Epigallocatechin-3-Gallate Stimulates Face Remodeling in Down Syndrome
John M. Starbuck, Sergi Llambrich, Rubèn González, Julia Albaigès, Anna Sarlé, Jens Wouters, Alejandro González, Xavier Sevillano, James Sharpe, Rafael De La Torre, Mara Dierssen, Greetje Vande Velde and Neus Martínez-Abadías
Received Date: 26th October 18
Trisomy 21 alters the development of multiple organ systems, including the face and underlying skeleton. Epigallocatechin-3-gallate (EGCG), a green tea flavonoid, has therapeutic potential for alleviating Down syndrome cognitive impairment and skeletal deficiencies. Here we provide the first evidence showing that EGCG can modulate facial development, with dose-dependent effects. Down syndrome mouse models treated with low doses of EGCG showed improved facial anatomy, whereas high doses of EGCG produced unpredictable facial shape changes, ranging from wild-type to exacerbated trisomic phenotypes. In humans, EGCG supplementation during the first three years of development dramatically reduced facial dysmorphology. Our findings suggest that low doses of EGCG may produce a beneficial effect on facial development of children with Down syndrome, but warn against non-prescribed high dose EGCG intake.
Read in full at bioRxiv.
This is an abstract of a preprint hosted on an independent third party site. It has not been peer reviewed but is currently under consideration at Nature Communications.